Process to inhibit binding of the integrin .alpha.4.beta.1 , to VCAM-1 fibronectin and cyclic peptides thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 30, 2004
Issued Date -
N/A
app pub date -
May 8, 1996
filing date -
Jun 29, 1994
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention is directed to an isolated and purified cyclic peptide of from 5 to about 13 residues modeled after a portion of the CS1 peptide. A peptide of this invention preferably has the amino acid residue sequence of SEQ ID NO:2-14 or 16-42. The present invention is further directed to a process of selectively inhibiting the binding of .alpha..sub.4.beta..sub.1 integrin to a protein such as VCAM-1, fibronectin or invasin. In accordance with that process, a cell that expresses .alpha..sub.4.beta..sub.1 integrin is exposed to that protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition containing a physiologically acceptable carrier and a cyclic peptide of the invention.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully